ConductScience.org, home

Paper30119081

Bevacizumab and Glioblastoma: Past, Present, and Future Directions.

Kim MM and 2 others. Cancer J, 2018. Cited by 94 papers, by iCite.

Cite this record

ConductScience Library. Bevacizumab and Glioblastoma: Past, Present, and Future Directions. Papers, record 30119081. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30119081

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bevacizumab and Glioblastoma: Past, Present, and Future Directions.
PubMed
Journal
Cancer J
PubMed
Year
2018
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
94
iCite
Relative citation ratio, by iCite
3.68
iCite
Revised in PubMed
2019-06-04
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kim MMMichelle M
2Umemura YYoshie
3Leung DDenise

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Angiogenesis InhibitorsMajor topic
Antineoplastic Agents, ImmunologicalMajor topic
BevacizumabMajor topic
GlioblastomaMajor topic
Animals
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Clinical Trials as Topic
Humans
Immunomodulation
Molecular Targeted Therapy
Recurrence
Treatment Outcome
Vascular Endothelial Growth Factor A

Source PubMed

Download CSV of topics

Cited by62

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.

PMIDTitleJournalYearIn PapersSource
42017986Interactions and communications in the glioblastoma microenvironment: potential targets for chemo-/radiotherapy.Strahlenther Onkol2026https://conductscience.org/library/papers/42017986PubMed
41758210KDM6B promotes VEGFA expression and vasculogenic mimicry in glioblastoma cells under hypoxia conditions.Exp Brain Res2026https://conductscience.org/library/papers/41758210PubMed
41495049Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial.Nat Commun2026https://conductscience.org/library/papers/41495049PubMed
40917884Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma.iScience2025https://conductscience.org/library/papers/40917884PubMed
40701845Fimepinostat is a dual inhibitor of tumor and angiogenesis in glioblastoma and synergizes with temozolomide through suppressing MYC.Korean J Physiol Pharmacol2025https://conductscience.org/library/papers/40701845PubMed
40699793Could Fingolimod Combined with Bevacizumab Be a New Hope in Glioblastoma Treatment?Curr Issues Mol Biol2025https://conductscience.org/library/papers/40699793PubMed
39893170Network analyses of brain tumor multiomic data reveal pharmacological opportunities to alter cell state transitions.NPJ Syst Biol Appl2025https://conductscience.org/library/papers/39893170PubMed
39575164Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.Cancer Manag Res2024https://conductscience.org/library/papers/39575164PubMed
39484048Tumor treating induced fields: a new treatment option for patients with glioblastoma.Front Neurol2024https://conductscience.org/library/papers/39484048PubMed
39308833Comparative Volumetric Analyses Following Bevacizumab Therapy for a Patient With Concomitant Glioblastoma, Meningioma, and Dural Arteriovenous Fistula: A Case Report and Review of Literature.Cureus2024https://conductscience.org/library/papers/39308833PubMed
39061228Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost.Cancers (Basel)2024https://conductscience.org/library/papers/39061228PubMed
38848215Lineage specification in glioblastoma is regulated by METTL7B.Cell Rep2024https://conductscience.org/library/papers/38848215PubMed
38803685Expression of the apelin receptor, a novel potential therapeutic target, and its endogenous ligands in diverse stem cell populations in human glioblastoma.Front Neurosci2024https://conductscience.org/library/papers/38803685PubMed
38716237Direct antitumor activity of bevacizumab: an overlooked mechanism?Front Pharmacol2024https://conductscience.org/library/papers/38716237PubMed
38484377[Systemic treatment of adult gliomas: a narrative review].Magy Onkol2024https://conductscience.org/library/papers/38484377PubMed
38258110Targeted Glioma Therapy-Clinical Trials and Future Directions.Pharmaceutics2024https://conductscience.org/library/papers/38258110PubMed
37762559Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers.Int J Mol Sci2023https://conductscience.org/library/papers/37762559PubMed
37686584The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma.Cancers (Basel)2023https://conductscience.org/library/papers/37686584PubMed
37548850First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial.J Neurooncol2023https://conductscience.org/library/papers/37548850PubMed
37540556Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.Clin Cancer Res2023https://conductscience.org/library/papers/37540556PubMed

See all 62 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30119081

GET https://conductscience.org/api/papers/v1/30119081/cited_by?page=2